Filter
102
Filtered Results: 102
Text search:
sinopharm
Featured
Recommendations
9
New Publications
2
Language
Document type
Guidelines
34
Studies & Reports
24
Fact sheets
14
Manuals
12
No document type
6
Situation Updates
5
Strategic & Response Plan
4
Resource Platforms
2
Infographics
1
Countries / Regions
Argentina
14
Brazil
6
Senegal
5
Global
4
Paraguay
4
Ukraine
3
Mozambique
3
Germany
3
West and Central Africa
3
East and Southern Africa
3
Colombia
2
Kenya
2
Rwanda
2
Chile
2
Syria
2
Nigeria
2
Latin America and the Carribbean
2
Middle East and North Africa
2
Switzerland
1
El Salvador
1
Benin
1
Congo-Brazzaville
1
Peru
1
Zimbabwe
1
Austria
1
Africa
1
Guinea-Bissau
1
Tanzania
1
South–East Asia Region
1
Namibia
1
Ethiopia
1
Angola
1
Chad
1
Ecuador
1
Authors & Publishers
Publication Years
Category
COVID-19
46
Guidelines
17
Studies & Reports
10
Policies
5
Policies & Guidelines HIV & TB
3
Women & Child Health
3
Pediatrics
2
Medical Devices & Equipment
2
Information, Education and Communication (IEC)
2
Hepatitis
1
Non-communicable Diseases NCD
1
Vaccine-preventable Diseases
1
Demograhic Health Surveys DHS
1
Drugs & Medical Equipment
1
Community Health
1
Capacity Building
1
Humanitarian Crisis
1
Statistics
1
Health Systems
1
Protection & Security
1
Non-communicable Diseases
1
Pharmacy & Technologies
1
Toolboxes
Country specific documents
35
Immunization Guidelines
7
Inactivated COVID-19 Vaccines
7
Booster Doses
6
Hospital Readiness/Essential Health Services
5
Communication Material
4
Essential Medicines
4
Infection Control General
3
For General Public & Community
3
Educational Settings
3
Workplace
3
Physical Distancing
3
Vaccine Hesitancy & Myths
3
Biontech/Pfizer Comirnaty
3
Vaccination
2
Clinical Guidelines
2
For Pregnant Women
2
Global Impact: Socio-economic, health services, TB & HIV
2
Infection Control & Prevention (IPC)
2
Access & Strategy
2
Moderna
2
Johnson & Johnson
2
Prices and Patents
2
Argentina
2
Accessibility
1
Inclusion in Humanitarian Settings
1
Pediatrics
1
Policies
1
SOPs
1
Situation Reports & Updates
1
Prevention & Preparedness
1
General
1
Public Health
1
Poster & Infographics
1
COVID-19 Information
1
For Parents & Children
1
Appeals and Response Plans
1
Dashboards & Maps
1
Country-specific Platforms
1
Paediatrics
1
HIV and COVID-19
1
COVID-19 Vaccination
1
Non-pharmaceutical interventions (NPIs)
1
Dashboards & Resource Platforms
1
Logistics & Supply
1
Fair Allocation & Ethical Aspects
1
Vaxzevria (Astra Zeneca)
1
Sputnik V
1
Research & Pipeline
1
Sanitation
1
Peru
1
Pharmacy Practice
1
Waste Managment
1
Reports & Studies
1
Situation Reports & Updates
1
Guidelines & Manuals
1
Information Refugees Ukraine
1
WASH Water Sanitation & Hygiene
1
General
1
COVID-19
1
Clinical Aspects & Diagnosis
1
Prevention & Strategies
1
Global Overview
1
Detection & Diagnosis
1
Drug resistant TB
1
Policies and guidelines
1
Situation Reports & Updates
1
Human Rights & the Right to Health
1
Research & Access
1
HIV service delivery
1
French version of "Developing Pharmacy Practice" - WHO/FIP Joint handbook - Ce manuel expose un nouveau paradigme de pratique pharmaceutique. Il a pour but de guider les enseignants en pharmacie pour qu’ils intègrent cette nouvelle pratique pharmaceutique, de former les étudiants ...
Übertragung
Symptome
Vorbeugung
Behandlung
Will COVID-19 vaccines be safe? Will all the COVID-19 candidate vaccines be successful? What are the different phases a vaccine must go through to be approved? This document provides responses to the most frequently asked questions about candidate vaccines and access to COVID-19 vaccination.
African Union and the Africa Centers for Disease Control and Prevention’s Africa Regulatory Taskforce has endorsed the Emergency Used Authorization for Janssen COVID-19 Vaccine
10 March 2021
24 September 2021. The vaccine has been authorized by the Chinese National Regulatory Authority (NRA) – the National Medicinal Product Administration (NMPA) – as well as other regulatory authorities. Because WHO has granted Emergency Use Listing (EUL) for the COVID-19 Vaccine BIBP/ Sinopharm, th...
24 September 2021. The vaccine has been authorized by the Chinese National Regulatory Authority (NRA) – the National Medicinal Product Administration (NMPA) – as well as other regulatory authorities. Because WHO has granted Emergency Use Listing (EUL) for the Sinovac COVID-19 vaccine (Vero Cell ...
These WHO interim recommendations for use of the COVID-19 vaccine BIBP produced by Sinopharm were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document and annexes referenced below.
Th...
Interim guidance, 26 October 2021
This interim guidance has been developed on the basis of the advice issued by the Strategic Advisory Group of Experts (SAGE) on Immunization at its meeting on 5 October 2021.
SAGE said moderately and severely immunocompromised persons should be offered an addition...
Overview
16 Dec 2021. This interim guidance pertains to heterologous primary and heterologous boosting schedules of Covid-19 vaccines. It focuses on heterologous schedules combining multiple vaccine platforms (e.g. a vectored vaccine followed by an mRNA vaccine).
Guidelines for the Vaccination Scheme against
COVID 19: Booster Dose Health Personnel
Position paper on vaccination with Sputnik V vaccine | National Commission on Vaccine Safety (CoNaSeVa) | 12 May 2021
Vaccinator's Manual SINOPHARM Vaccine - 28 FEBRUARY 2021
PHARMA’S RESPONSE TO THE COVID-19 VACCINES CRISIS. Update Feb., 14, 2022. In September 2021, Amnesty International published A Double Dose of Inequality, which assessed the extent to which the pharmaceutical industry was restricting access to Covid-19 vaccines. This report updates that assessment ...
O SAGE aplica os princípios da medicina baseada em evidências e estabeleceu um processo metodológico completo para emitir ou atualizar recomendações. Especificamente para vacinas contra a COVID-19, uma descrição detalhada dos processos metodológicos pode ser encontrada no esquema de evidênc...
En Paraguay, la vacunación contra COVID-19 inició el 22 de febrero de 2021. Se han autorizado un total de siete vacunas: Bharat-Covaxin, Moderna, Pfizer-BioNTech, AstraZeneca, Sinopharm, Sputnik V- Gamaleya y CoronaVac-Sinovac. Los grupos prioritarios de vacunación están definidos según el Plan...
